JP2025508932A5 - - Google Patents
Info
- Publication number
- JP2025508932A5 JP2025508932A5 JP2024551922A JP2024551922A JP2025508932A5 JP 2025508932 A5 JP2025508932 A5 JP 2025508932A5 JP 2024551922 A JP2024551922 A JP 2024551922A JP 2024551922 A JP2024551922 A JP 2024551922A JP 2025508932 A5 JP2025508932 A5 JP 2025508932A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- heart disease
- person suffering
- grk5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315118P | 2022-03-01 | 2022-03-01 | |
| US63/315,118 | 2022-03-01 | ||
| PCT/US2023/063451 WO2023168246A2 (en) | 2022-03-01 | 2023-03-01 | Selective g protein-coupled receptor kinase 5 inhibitors, compositions, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508932A JP2025508932A (ja) | 2025-04-10 |
| JP2025508932A5 true JP2025508932A5 (enExample) | 2026-03-05 |
Family
ID=87884331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551922A Pending JP2025508932A (ja) | 2022-03-01 | 2023-03-01 | 選択的ｇタンパク質共役受容体キナーゼ５阻害剤、組成物、及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250388567A1 (enExample) |
| EP (1) | EP4486335A4 (enExample) |
| JP (1) | JP2025508932A (enExample) |
| KR (1) | KR20240169624A (enExample) |
| CN (1) | CN118891039A (enExample) |
| AU (1) | AU2023228660A1 (enExample) |
| CA (1) | CA3244988A1 (enExample) |
| IL (1) | IL315279A (enExample) |
| WO (1) | WO2023168246A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119350363A (zh) * | 2024-10-22 | 2025-01-24 | 中国药科大学 | 一类protac分子及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035721A1 (es) * | 2000-12-20 | 2004-07-07 | Sugen Inc | Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa |
| CN102276584A (zh) * | 2010-06-08 | 2011-12-14 | 齐鲁制药有限公司 | 吡咯取代的2-二氢吲哚酮衍生物、其制备方法及用途 |
| CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| EP2837626A1 (en) * | 2013-08-16 | 2015-02-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Indolinone derivatives as GRK5 modulators |
| WO2021243040A2 (en) * | 2020-05-29 | 2021-12-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof |
-
2023
- 2023-03-01 US US18/843,111 patent/US20250388567A1/en active Pending
- 2023-03-01 EP EP23764065.1A patent/EP4486335A4/en active Pending
- 2023-03-01 IL IL315279A patent/IL315279A/en unknown
- 2023-03-01 CN CN202380024914.9A patent/CN118891039A/zh active Pending
- 2023-03-01 WO PCT/US2023/063451 patent/WO2023168246A2/en not_active Ceased
- 2023-03-01 JP JP2024551922A patent/JP2025508932A/ja active Pending
- 2023-03-01 AU AU2023228660A patent/AU2023228660A1/en active Pending
- 2023-03-01 CA CA3244988A patent/CA3244988A1/en active Pending
- 2023-03-01 KR KR1020247032184A patent/KR20240169624A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022020624A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 | |
| RU2450813C2 (ru) | Гипотензивная комбинация валсартана и блокатора кальциевых каналов | |
| JP2021063088A5 (enExample) | ||
| DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
| JP2010077141A5 (enExample) | ||
| RU2010144131A (ru) | Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний | |
| JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤 | |
| JP2007522135A5 (enExample) | ||
| JP2022552881A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP7471685B2 (ja) | 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 | |
| JP2020520948A5 (enExample) | ||
| EA201992801A1 (ru) | Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения | |
| CN102307861B (zh) | 苯基咪唑化合物 | |
| JP2021530488A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| WO2017006254A1 (en) | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist | |
| JP6839097B2 (ja) | 医薬 | |
| JP4608093B2 (ja) | 組合せ製剤としてのエンドセリン拮抗剤およびβ−受容体ブロッカー | |
| JP2022544803A5 (enExample) | ||
| PE20240242A1 (es) | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico | |
| CN1147765A (zh) | 肺性心病治疗剂 | |
| JP2024543259A5 (enExample) | ||
| CN102196809B (zh) | 糖尿病性肾病的治疗剂 | |
| JP2025513384A5 (enExample) | ||
| CN101102775A (zh) | 采用pdev抑制剂治疗充血性心衰的方法 |